Please assess the completion status of the following clinical trial:

Trial Title: Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Arterial pO2 8 kPa or lower, and arterial pCO2 7 kPa or higher.~* Base Excess 8 mmmol/l or higher.~* Written informed consent~Exclusion Criteria:~* Acetazolamide treatment regarded as obviously indicated or obviously contraindicated~* Already using acetazolamide~* Moribund patient~* Unable to give fully informed consent~* Allergy towards the tablet content or unable to swallow the tablets~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acetazolamide (Type: EXPERIMENTAL): Acetazolamide 250 mg Three times a day for five days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, one tablet Three times a day for five days

Based on this trial design, predict the completion outcome and termination type (if applicable).